Mercachem logo voor websites


Update COVID-19:

The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.

The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.


 

p38 MAP

 

We proudly share with you a J. Med. Chem. article about highly selective type-II kinase inhibitors. For this article Mercachem scientists were involved in the design and synthesis of these inhibitors, the project being a spin-off from our internal innovation projects.

"We are honored to have had the opportunity to collaborate with the groups of Prof. Dr. Stefan Knapp and Prof. Dr. Stefan Laufer, two experts in the area of kinase inhibitors," comments Dr. Koen Hekking. "By recognizing the trimodular nature of the original DNA-encoded library hit, and applying an iterative, semi-parallel approach to the different building blocks, our group managed to synthesize a diverse set of compounds. This eventually led to the identification of a highly selective inhibitor for the inactive states of p38α/β."

Mercachem continues investing in expertise and quality within several innovation projects,which are open for partnering.

Röhm, Sandra et al., J. Med. Chem, 2019 (62), 10757-10782, "Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors"

 

Find the article here  

Contact us